ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics Post published:November 22, 2025 Post category:Analysis/News/Pα+
AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 Post published:November 10, 2025 Post category:Analysis/News/Pα+
Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months Post published:November 4, 2025 Post category:Analysis/News/Pα+
Q3’25 Investor Survey: What are Investors Most Concerned About? Post published:October 23, 2025 Post category:Analysis/News/Pα+
Q3’25 Survey: What are Psychedelics Investors Excited About? Post published:October 21, 2025 Post category:Analysis/News/Pα+
Q2 2025: Oregon Psilocybin Services Update Post published:October 10, 2025 Post category:Analysis/News/Pα+
Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study Post published:September 22, 2025 Post category:Analysis/News/Pα+